Login / Signup

Impact of Performance Status on Response and Survival Among Patients Receiving Checkpoint Inhibitors for Advanced Solid Tumors.

Mridula KrishnanPooja KasinathRobin HighFang YuBenjamin A Teply
Published in: JCO oncology practice (2021)
Despite the appeal of ICI in patients with advanced malignancy and poor PS, outcomes in this cohort were poor. Prospective trials defining the activity and role of ICI in poor PS are urgently needed.
Keyphrases
  • dna damage
  • cell cycle
  • type diabetes
  • weight loss